We are really excited about the data from our three-month non-human primate studies, where we are seeing 50% to 73% knockdown of tau messenger RNA, quite broadly across the brain. We have ...

Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Analysts anticipate that Neurocrine Biosciences will post 4.28 EPS for the current year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The new indication brings the drug into direct competition with Ongentys from rival Neurocrine Biosciences, which was approved for the same use last year. Adamas noted that Gocovri (amantadine ...

Voyager Therapeutics Inc. (VYGR) released its Q4 2024 earnings report, revealing a significant miss on earnings per share (EPS) forecasts. The company reported an EPS of -0.37, which aligned with ...

Voyager Therapeutics Inc. (VYGR) released its Q4 2024 earnings report, revealing a significant miss on earnings per share (EPS) forecasts. The company reported an EPS of -0.37, which aligned with ...

Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...